Company intelligence / Profile preview

Revobiom

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Revobiom has developed a proprietary high-throughput millifluidic platform—the Microbial Evolution Machine—that enables rapid directed evolution of entire microbiomes or microbial consortia. The system uses hundreds of miniaturized bioreactors (“droplet trains”) with real-time optical monitoring to select for desired traits. The technology has been validated in laboratory settings and through initial industrial trials with partners such as Eurogerm. No clinical results are available as the primary focus is currently agricultural/industrial applications rather than direct therapeutic use in humans or animals[1][2].

Modalities: Live biotherapeutic product therapyMicrobial therapyPlatform technology
Industry: Non-Drug Biotech

Partnerships

Eurogerm

Beyond the preview

Go deeper on Revobiom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revobiom.

Explore the full profile